Patents by Inventor Anthony Piscopio

Anthony Piscopio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AKT PROTEIN KINASE INHIBITORS
    Publication number: 20160152576
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 31, 2014
    Publication date: June 2, 2016
    Applicant: Array BioPharma, Inc.
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicolas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • AKT PROTEIN KINASE INHIBITORS
    Publication number: 20140148436
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: Array BioPharma, Inc.
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicolas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • AKT protein kinase inhibitors
    Patent number: 8680114
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: March 25, 2014
    Assignees: Array Biopharma, Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicholas C. Kallan, Mark Munson, Guy P. A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • AKT PROTEIN KINASE INHIBITORS
    Publication number: 20100168123
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: September 25, 2009
    Publication date: July 1, 2010
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicholas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • Method of Preparing a Ring Compound Having Two Adjacent Chiral Centers
    Publication number: 20070276145
    Abstract: A method of synthesizing a chiral compound having a quaternary carbon atom bearing diastereotopic groups from (a) a nitroolefin and (b) an ?-substituted ?-dicarbonyl or an equivalent compound having an acidic C—H moiety compound is disclosed. A subsequent intramolecular reaction between one of the substituents comprising the stereogenic carbon atom and one of the diastereotopic groups comprising the quaternary carbon atom creates a new compound having two contiguous stereogenic centers, one of which is quaternary, with control over the relative stereochemistry.
    Type: Application
    Filed: April 19, 2004
    Publication date: November 29, 2007
    Applicant: ICOS CORPORATION
    Inventors: Lisa Schultze, John Demattei, Brad Barnett, Anthony Piscopio, Paul Nichols
  • AKT protein kinase inhibitors
    Publication number: 20050130954
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: November 19, 2004
    Publication date: June 16, 2005
    Inventors: Ian Mitchell, Keith Spencer, Peter Stengel, Yongxin Han, Nicholas Kallan, Mark Munson, Guy Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Riu Xu, Chang Rao, Bin Wang, April Bernacki
  • Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
    Patent number: 6509337
    Abstract: A compound of the formula wherein R1-R9 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidemrolysis bullosa, scleritis and other disease characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: January 21, 2003
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, James P. Rizzi
  • Processes and intermediates for preparing substituted chromanol derivatives
    Patent number: 6444826
    Abstract: The invention relates to processes for preparing a compound of the formula and the enantiomer of said compound, wherein the benzoic acid moiety is attached at position 6 or 7 of the chroman ring, and R1, R2, and R3 are as defined herein. The invention further relates to intermediates that are useful in the preparation of the compound of formula X above.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: September 3, 2002
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephane Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Processesand intermediatesfor preparing substitutedchromanol derivatives
    Publication number: 20020099227
    Abstract: The invention relates to processes for preparing a compound of the formula 1
    Type: Application
    Filed: October 31, 2001
    Publication date: July 25, 2002
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephane Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Processesand intermediatesfor preparing substitutedchromanol derivatives
    Publication number: 20020042526
    Abstract: The invention relates to processes for preparing a compound of the formula 1
    Type: Application
    Filed: March 21, 2001
    Publication date: April 11, 2002
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephanie Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Processes and intermediates for preparing substituted chromanol derivatives
    Patent number: 6355825
    Abstract: The invention relates to processes for preparing a compound of the formula and the enantiomer of said compound, wherein the benzoic acid moiety is attached at position 6 or 7 of the chroman ring, and R1, R2, and R3 are as defined herein. The invention further relates to intermediates that are useful in the preparation of the compound of formula X above.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: March 12, 2002
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephanie Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Processes and intermediates for preparing substituted chromanol derivatives
    Patent number: 6288242
    Abstract: The invention relates to processes for preparing a compound of the formula and the enantiomer of said compound, wherein the benzoic acid moiety is attached at position 6 or 7 of the chroman ring, and R1, R2, and R3 are as defined herein. The invention further relates to intermediates that are useful in the preparation of the compound of formula X above.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: September 11, 2001
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephanie Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Processes for preparing substituted chromanol derivatives
    Patent number: 6096906
    Abstract: The invention relates to processes for preparing a compound of the formula (X) and the enantiomer of said compound, wherein the benzoic acid moiety is attached at position 6 or 7 of the chroman ring, and R.sup.1, R.sup.2 and R.sup.3 are as defined herein. The invention further relates to intermediates that are useful in the preparation of the compound of formula (X).
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: August 1, 2000
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephane Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
    Patent number: 5861510
    Abstract: A compound of the formula ##STR1## wherein R.sup.1, R.sup.2 R.sup.3, R.sup.4 R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and Ar are as defined above, useful in the treatment of a condition seiected from the group consisting of arthritis, cancer, tisuue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other disease characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: January 19, 1999
    Assignee: Pfizer Inc
    Inventors: Anthony Piscopio, James P. Rizzi